kaznar_manutencao

Brazil: Patent Litigation 2023 – IAM Media

Our partner Claudio Barbosa and our Attorney at Law Viviane Trojan are the authors of the article “Brazil: Patent Litigation”, published in the Global Patent Brazil: Patent Litigation 2023 – IAM Media

CFM updates its Resolution on cannabidiol prescription and use

The Federal Council of Medicine (CFM) published, on 10/14/2022, CFM Resolution No. 2,324/22, which authorizes the use of cannabidiol (CBD) for treatment CFM updates its Resolution on cannabidiol prescription and use

Copyright registration in Brazil may now be submitted via online system

While registration is not mandatory in Brazil for copyright protection, it is a recommended measure as it may serve as evidence of Copyright registration in Brazil may now be submitted via online system

Brazilian Patent Office (BPO) announces that the limit of PPH requests for 2022 has been reached

The Brazilian Patent Office (BPO) announced on September 29, 2022, that the limit of PPH (Patent Prosecution Highway) requests for the year Brazilian Patent Office (BPO) announces that the limit of PPH requests for 2022 has been reached

ANVISA approves new Resolution RDC related to Medical Devices

ANVISA published, in the Federal Official Gazette, RDC No. 751/2022, which provides and defines, in relation to medical devices, the (i) risk classification rules; (ii) labeling ANVISA approves new Resolution RDC related to Medical Devices

Combined products in Brazil – brief comments on Anvisa’s (Brazilian National Health Surveillance Agency) current understanding

The new generations of products are the result of the increasing combination of different technologies, leading to a crossing of borders between Combined products in Brazil – brief comments on Anvisa’s (Brazilian National Health Surveillance Agency) current understanding

Brazilian National Health Surveillance Agency authorizes exceptional drug and vaccine use against Monkeypox by the Ministry of Health

The Ministry of Health (MH) sent Brazilian National Health Surveillance Agency (Anvisa) a request for exemption from the sanitary registration, on an Brazilian National Health Surveillance Agency authorizes exceptional drug and vaccine use against Monkeypox by the Ministry of Health

Brazilian National Health Surveillance Agency (ANVISA) decides to ban Carbendazim

On August 8th, 2022, during the 12th Extraordinary Public Meeting of DICOL, ANVISA’s Collegiate Board of Directors announced the completion of the toxicological Brazilian National Health Surveillance Agency (ANVISA) decides to ban Carbendazim

Protecting Plant Varieties in Brazil for FloraCulture Magazine

Our partner and head of Life Sciences, Priscila Kashiwabara discusses plant variety protection in Brazil and its recent developments regarding legal framework for Plant Protecting Plant Varieties in Brazil for FloraCulture Magazine

Carbendazim toxicological revaluation about to be completed by ANVISA

In December 2019, ANVISA started the process of toxicological revaluation of the Active Ingredient (AI) Carbendazim, as signs of toxicity were identified Carbendazim toxicological revaluation about to be completed by ANVISA